Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA4 | P22748 | 1/20 | 0.51 |
| ▸ | CA6 | P23280 | 1/20 | 0.51 |
| ▸ | CA5A | P35218 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.51 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31347322 | 1.00 | ATM (0.54) | ATMHTTPOLBSMN1; SMN2USP2 | |
| SCHEMBL27345125 | 0.86 | ATM (0.63) | ATMHTTPOLBSMN1; SMN2USP2 | |
| SCHEMBL992863 | 0.86 | ATM (0.58) | ATMHTTPOLBSMN1; SMN2USP2 | |
| SCHEMBL6609176 | 0.86 | CA1 (0.55) | POLBTSHRKDM4ECA1CA2 | |
| SCHEMBL6034118 | 0.83 | PKM (0.58) | ATMHTTPOLBSMN1; SMN2USP2 | |
| SCHEMBL2375629 | 0.82 | ATM (0.54) | ATMHTTPOLBSMN1; SMN2USP2 | |
| SCHEMBL6034955 | 0.81 | ATM (0.50) | ATMHTTPOLBSMN1; SMN2USP2 | |
| SCHEMBL22659134 | 0.81 | RAB9A (0.66) | ATMHTTPOLBSMN1; SMN2USP2 | |
| SCHEMBL1491825 | 0.79 | L3MBTL1 (0.72) | ATMHTTUSP2TSHRL3MBTL1 | |
| SCHEMBL30005678 | 0.79 | LMNA (0.50) | HTTPOLBSMN1; SMN2TSHRCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | ASTRAZENECA (SE) | 2006-03-09 | — | — | US | claimed |
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | claimed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | claimed |
| US-20160193206-A1 | BET-PROTEIN-INHIBITING DIHYDROPYRIDOPYRAZINONES | Bayer Pharma AG (DE) | 2016-07-07 | — | — | US | disclosed |
| US-20160193206-A1 | BET-PROTEIN-INHIBITING DIHYDROPYRIDOPYRAZINONES | Bayer Pharma AG (DE) | 2016-07-07 | — | — | US | disclosed |
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | ASTRAZENECA (SE) | 2006-03-09 | — | — | US | disclosed |
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193206-A1 | BET-PROTEIN-INHIBITING DIHYDROPYRIDOPYRAZINONES | BRD4, BET1, BRDT | ATM 1623/4885HTT 232/4885POLB 474/4885 |
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | GSK3A, GSK3B, PYGL | ATM 1066/4885HTT 923/4885POLB 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.